BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 24, 2003
 |  BioCentury  |  Product Development

Needed: A dose of patience

Although Isis Pharmaceuticals Inc.'s Vitravene fomivirsen for CMV retinitis provided the initial proof-of-principle for antisense technology, investors have been waiting for results of the Phase III study of ISIS's Affinitak for definitive proof that antisense can serve as a true technology platform for major drugs. They will have to wait longer.

Using primary log-rank statistical analysis, data from the trial conducted by ISIS showed there was no difference in overall survival between patients who received Affinitak plus chemotherapy versus those who received chemotherapy alone (see B10).

"It wasn't the homerun we hoped for, but it is another step along a very long trip we're taking," Chairman and CEO Stanley Crooke told BioCentury.

ISIS (Carlsbad, Calif.) and partner Eli Lilly and...

Read the full 598 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >